Addition of maintenance olaparib slows advanced ovarian cancer

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovarian cancer, according to a study published in the Dec. 19 issue of the New England Journal of Medicine.

Isabelle Ray-Coquard, M.D., Ph.D., from the Centre Léon Bérard in Lyon, France, and colleagues conducted a randomized, phase 3 trial involving with newly diagnosed, advanced, high-grade ovarian cancer who had a response after first-line platinum-taxane chemotherapy plus bevacizumab. Eligibility was not linked to patients' surgical outcome or BRCA mutation status. Overall, 806 patients were randomly assigned to receive either olaparib or placebo in a 2:1 ratio for up to 24 months (537 and 269, respectively); all patients received bevacizumab.

The researchers found that the was 22.1 months with olaparib plus bevacizumab and 16.6 months with placebo plus bevacizumab after a median follow-up of 22.9 months (hazard ratio for disease progression or death, 0.59). For or death, the hazard ratios were 0.33 and 0.43 for patients with tumors positive for homologous-recombination deficiency, including tumors that had BRCA mutations (median progression-free survival, 37.2 versus 17.7 months) and tumors that did not have BRCA mutations (median progression-free survival, 28.1 versus 16.6 months).

"The trial met its primary objective by showing a significant progression-free survival benefit in the intention-to-treat population," the authors write.

Several authors disclosed financial ties to , including AstraZeneca (the manufacturer of olaparib), Merck Sharp & Dohme, and F. Hoffmann-La Roche, which partially funded the study.

Explore further

Ovarian cancer: more women benefit from maintenance combined targeted therapy

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal information: New England Journal of Medicine

Copyright © 2019 HealthDay. All rights reserved.

Citation: Addition of maintenance olaparib slows advanced ovarian cancer (2019, December 19) retrieved 11 July 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments